DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will deliver an oral presentation at the Hep-DART 2025 meeting, to take place December 7–11, 2025, at the Hilton Hawaiian Village in Honolulu, Hawaii. The presentation will feature data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV. "We ar. ...

Core Viewpoint - Precision BioSciences, Inc. has announced an underwritten offering to sell 10,815,000 shares of its common stock along with warrants to purchase up to 5,407,500 additional shares at a combined price of $6.14 [1] Company Summary - The company is a clinical stage gene editing firm utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies targeting diseases with high unmet needs [1] - The offering includes both common stock and accompanying warrants, indicating a strategy to raise capital for further development [1]

Summary of Verve Therapeutics (VERV) 2025 Conference Call Company Overview - **Company**: Verve Therapeutics - **Focus**: Atherosclerotic cardiovascular disease (ASCVD) and LDL cholesterol management through gene editing technology [3][4] Key Points and Arguments 1. **Unmet Need in Cholesterol Management**: Approximately 50% of patients discontinue LDL-lowering medications within a year, highlighting a significant unmet need for long-term cholesterol management solutions [4][5] 2. **Innovative Approach**: Verve is developing a one-time gene editing therapy (Vrb102) that targets the PCSK9 gene to achieve lifelong LDL reduction. This therapy aims to provide a durable solution to cholesterol management [4][5][6] 3. **Phase 1 Data**: - The Phase 1 trial involved 14 patients across three dose levels, showing a mean LDL reduction of 59% at the highest dose, with a maximum reduction of 69%. All participants in the high-dose group experienced over 50% reduction [5][6][24] - The therapy demonstrated excellent safety, with no significant adverse effects observed in liver function tests [6][17] 4. **Partnership with Eli Lilly**: Verve has an ongoing partnership with Eli Lilly, with expectations for Lilly to opt into the program in the second half of the year based on the Phase 1 data [7][21][22] 5. **Future Milestones**: Key upcoming events include the full dose escalation results, Lilly's opt-in decision, and the initiation of Phase 2 trials [21][22] Additional Important Content 1. **Dosing Strategy**: Transitioning from weight-based dosing to fixed RNA doses in Phase 2 trials, as the amount of RNA delivered appears to correlate with pharmacodynamics [10][12] 2. **Market Opportunity**: - The potential market for heterozygous familial hypercholesterolemia (HEFH) is approximately 3 million patients in the US and Europe, while ASCVD affects about 25 million [39][40] - Early adopters are expected to be younger patients requiring long-term LDL care, who currently face burdensome treatment regimens [41][42] 3. **Pricing Strategy**: The anticipated cost of manufacturing for the gene therapy is manageable, estimated at around $1,500 per dose, allowing for competitive pricing compared to traditional therapies [46][48] 4. **Pipeline Development**: Verve is also developing therapies targeting ANGPTL3 and lipoprotein(a), with ongoing clinical trials and partnerships with Eli Lilly for these products [50][52][58] 5. **Financial Position**: As of Q1, Verve has approximately $500 million in cash, providing a runway until mid-2027 to support ongoing and upcoming clinical trials [54] This summary encapsulates the critical insights and developments discussed during the Verve Therapeutics conference call, emphasizing the company's innovative approach to addressing cardiovascular disease through gene editing technology.